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CHAPTER 4
Im m u n o lo g y  a n d  Im m u n o th e ra p y  o f 
In tr in s ic  G lia l T u m o rs
William T. Couldwell, MD, Malcolm S. Mitchell, MD,
Amitabha Mazumder, MD, and Michael L.J. Apuzzo, MD
I m m u n o lo g ic a l a sp ects o f  g lia l n eop lasm s  
have b e e n  a c t iv e ly  in v e s t ig a t e d  for th e  p a st  
several years w ith  p articu lar  focus on  acad em ­
ic, d ia g n o s t ic , and  th era p eu tic  o b jec tiv e s . A s  
m ore k n o w le d g e  is a c q u ir e d  a b o u t  th e  c e l ­
lu lar  e v e n ts  r e la t in g  to  tu m o r  b eh a v io r  th e  
m ore it  appears th at th e  im m u n e  sy stem  is a 
p iv o ta l t o o l  for tu m o r  e v a lu a t io n . C o n c e iv ­
ab ly , it  m a y  p reva il as th e  u lt im a te  resource  
in  c o m b a t in g  tu m o r  g r o w th . In th is  l ig h t ,  it  
behooves a ll n eu ro su rg eo n s to  u n d erstan d  the  
b a s ic  f u n c t i o n a l  c o n c e p t s  o f  t h e  i m m u ­
n o lo g ic a l  s y s t e m  a n d  it s  r e le v a n c e  to  n e o ­
p la s t ic  g r o w th . C u rren t s ta n d a rd  th era p ie s  
have su r e ly  d o n e  l i t t l e  to  im p r o v e  th e  p o o r  
p r o g n o s is  m a n ife s t  in  p a t ie n ts  w ith  m a l ig ­
nant g l io m a .7,1
T h e  N o r m a l  I m m u n o l o g i c a l  
R e s p o n s e
T h e  n o r m a l  im m u n e  s y s t e m  h a s  th r e e  
basic ce llu la r  e lem en ts: th e  T -c e ll ,  th e  m a c ­
ro p h a g e , and  th e  B - c e l l .  T h e  T - c e l l  and  th e  
B -ce ll m a k e  up  th e  ly m p h o c y te  g r o u p , char­
a c ter ized  b y  a s iz e  r a n g in g  from  4 - 2 0  m m  
(sm all and  large) and a large  n u c leu s  sta in in g  
d eep  b lu e  w it h  W r i g h t ’s s t a in .  S u b s e t s  o f  
ly m p h o cy te s  m ay be d is t in g u ish e d  b y  m o le c ­
ular c o n f ig u r a t io n  o f  th e  c e l l  su rface  m e m ­
b r a n e s . C e l l s  d e f i n e d  as B - c e l l s  (B u r s a -  
d erived , in  th e  ch ick en ) are ch aracterized  by 
im m u n o g l o b u l i n  o n  t h e  c e l l  m e m b r a n e .
T h ese  c e lls  are p r im a r ily  con cern ed  w ith  the  
p r o d u c t io n  o f  c ir c u la t in g  im m u n o g lo b u l in  
and  th u s  c o m p r ise  th e  h u m o r a l arm  o f  th e  
im m u n e  re sp o n se . T -c e l l s  ( th y m u s  d e r iv e d )  
have th e  so -ca lled  th e ta -a n tig e n  on  th e ir  sur­
face  in  m ic e , an d  in  m a n , th e  C D 3  su rface  
a n tig e n . T h ey  also  possess a sp ec ific  receptor  
for a n t ig e n — a n a lo g o u s to , b u t n o t id en tica l 
w it h ,  th e  im m u n o g lo b u l in  s i t u a t e d  o n  B -  
ce lls . In  the p er ip h era l ly m p h  n od es th ey  re­
s id e  p r im a r ily  in  th e  d eep  s u b c o r t ic a l areas 
and  arou n d  th e  g e r m in a l cen ters. T h ese  cells  
are p r im a r ily  in v o lv e d  in  c e l l -m e d ia te d  im ­
m u n ity  (F igu re 1).
C e l l u l a r  I m m u n e  R e s p o n s e
T h e  so -c a lle d  c e l l -m e d ia te d  im m u n e  re­
sp o n se  is fo r e m o st  in  c o n s id e r a t io n  o f  a n t i ­
tu m o r  im m u n it y .  W h e n  s e n s it iz e d  T -c e lls  
and m acrop h ages are a c tiv a ted , th ey  are capa­
b le  o f  s e n s it i z in g  and  k i l l in g  tu m o r  c e l l s ,  a 
fu n c t io n  th a t  p r o b a b ly  o c c u r s  w it h  an  e x ­
p e c te d  s t a t i s t i c a l  f r e q u e n c y  in  th e  n o r m a l  
h o st . T h e  th y m u s-d e r iv e d  T -c e ll o r ig in a te s  in 
the b on e  m arrow  and  ach ieves im m u n o c o m -  
p e te n c e  th r o u g h  m a tu r a t io n  in  th e  th y m u s .  
T -c e l ls  res id e  in  a ll ly m p h a t ic  o rg a n s o f  th e  
b o d y  and  are s t im u la te d  in  th e  im m u n e  re­
sp on se  by m acrop h ages th at p rocess and p re­
se n t a n t ig e n , th e r e b y  e n a b lin g  in i t ia t io n  o f  
T -c e l l  a c t iv a t io n  (F ig u r e  2 ). In  th is  m a n n er  
th e  m acrop h age is the cen tra l c o m p o n e n t in
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F igure 1. Development o f the lymphoid system, Representation of the ontogeny of the immune response, showing differentia­
tion of progenitor cells into hemopoietic an d  immunocompetent cells.
With permission from Bellanci JA. bmmmln^ y III. Philadelphia, Pa: WD Saunders; 1985.
both th e  recogn ition  o f  a n t ig e n  and in it ia t io n  
o f  the im m u n e response.
As th e  T -c e li en ters  i t s  fu n c t io n a l or e f ­
fector phase, it  is capab le o f  d a m a g in g  or d e ­
s tr o y in g  tu m o r  c e l l s .  T h is  f u n c t io n  is d e ­
p e n d e n t u p o n  th e  r e le a se  o f  ly m p h o k in e s ,  
so lu b le  m ed iators th a t  a m p lify  th e  im m u n e  
response. L y m p h o k in es are h u m o ra l factors  
that in flu en ce  th e  fu n c t io n  o f  o th e r  e ffe c to r  
cells. O n e ly m p h o k in e , in te r le u k in -2  (IL -2), 
induces ly m p h o cy te  g r o w th , p r o life r a t io n , 
and d ifferen tiation . 16 Several o ther ly m p h o ­
kines have been characterized  and w ill  be d is ­
cussed in  detail later (T ab le 1 ).
The T -cells th em selves are a h etero g en eo u s  
group, encom passing several p h en o ty p ica lly  
different cell types. A n tig e n -d r iv e n  ly m p h o ­
cyte d ifferen tia tion  o f  T -c e l ls  a lters  th e  d is ­
p lay  o f  surface  m a c r o m o le c u le s .  T h e s e  so -  
called  d ifferen tia tio n  a n t ig e n s  h ave  b e c o m e
u s e f u l  as m a r k e r s  o f  c e l l  f u n c t io n .  S ev era l 
su b c la sse s  o f  T - ly m p h o c y te s  are r e c o g n iz e d ,  
b ased  on  e x p r e s s io n  o f  th ese  d if fe r e n t ia t io n  
an tig en s: th e  C D 8 p o s it iv e  cy to to x ic  (k iller) 
e ffec to r  c e ll;  th e  h e lp e r  T -c e l l ,  w ith  surface  
exp ress ion  o f  th e  C D 4  an tigen ; and th e  su p ­
pressor T -c e l l ,  a lso  w ith  surface exp ression  o f  
th e  C D 8 (fo rm erly  T 5  or T 8) a n t ig e n . 59 T h e  
h elp er  T -c e ll  a id s in  b o th  ce ll-m ed ia ted  im ­
m u n ity  an d  a n tib o d y  p ro d u ction ; norm al im ­
m u n e  r e sp o n se  to  a tu m o r  c e ll is d e p e n d e n t  
u p o n  th e  p resen ce  o f  an adequate n u m b er  and  
fu n c t io n  o f  th is  su b s e t  o f  ly m p h o cy tes . H e lp ­
er T -c e l l s  l ib e r a te  im p o r ta n t  c y to k in e s  su ch  
as th e  ly m p h o k in e s  d e s c r ib e d  a b o v e . T h e  
su ppressor T -c e l l  r eg u la tes  im m u n e  response  
to  a n t i g e n s ,  in c l u d i n g  tu m o r  a n t i g e n s . 23 
S u p p resso r  T - c e l l s ,  fo u n d  p r e d o m in a te ly  in  
th e  th y m u s  a n d  s p le e n  w it h in  2 4  h o u r s  o f  
a n t i g e n  e x p o s u r e ,  a p p e a r  to  l i m i t  t h e
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F ig u re  2 . Cellular interactions in the production o f antibody; note the central role of the macrophage 
(M 0 ) .  IL-2-Interleukin 2 , T/-helper T-cell. .
With permission irom Clark WR. The Experimental C'tnnuldtiom nf Mm/av Now York, NY: John W ile/ and Sons; 1986.
c y to ly tic  tu m o r  resp o n se  o f  th e  h o st (F igu re  
3). M ea su rem en ts  o f  th ese  surface m arkers in  
p er ip h era l b lo o d  ly m p h o c y te s  m a y  o ffer  in ­
s ig h t in  th e  overa ll im m u n e  sta tu s  o f  th e  in ­
d iv id u a l,
N a tu ra l k il le r  (N K )  c e lls  are p red o m in a n t­
ly n o n -T  ly m p h o c y te s  th a t  p o sse ss  in h e r e n t  
c y to to x ic  p r o p e r t ie s  to  p r e v e n t th e  d e v e lo p ­
m e n t  o f  tu m o r  c e l l s  in t o  f u l l - f l e d g e d  n e o ­
p lasm s. T h ese  ce lls  h ave  th e  ca p a b ility  o f  ly s-  
in g  t u m o r  c e l l s  in  v i t r o  w i t h o u t  p r io r  
s e n s i t i z a t io n . 26 T h e ir  s ig n i f i c a n c e  in  g l ia l  
n eop lasm s in  v iv o  is an a c tiv e  area o f  in v e s t i­
g a tio n .
M a cro p h a g es, as em p h a s ized  ab ove, are an 
in te g r a l e le m e n t  in  th e  n o rm a l im m u n e  re­
sp o n s e . T h e y  are in v o l v e d  in  a lm o s t  e v ery  
fa c e t  o f  t h e  r e s p o n s e . 54 T h e  c i r c u l a t i n g  
m o n o c y t e ,  t h e  p r o g e n i t o r  o f  th e  t i s s u e -  
r e s id in g  m a c r o p h a g e ,  is d e r iv e d  fr o m  th e  
sam e im m e d ia te  p recu rsor  as th e  g ra n u lo cy te . 
B lood  m o n o c y te s  arise  from  precursors in  th e
b o n e  m arrow  (F ig u re  1). M o n o cy tes  and m ac­
ro p h a g es  r e p r e se n t a fa m ily  o f  re la ted  p h a­
g o c y t i c  c e l l s  f o u n d  in  v a r io u s  ly m p h o id  
o r g a n s  ( s p le e n ,  l iv e r ,  ly m p h  n o d e s , b o n e  
m a rro w ) an d  a v a r ie ty  o f  b o d y  f lu id s . 58 T h e  
m acrop h age  serves a p ro cess in g  role for a n ti­
g e n ,  p r e s e n t in g  a n t ig e n  to  T -c e l ls ,  and  c o l­
laborates w ith  T -c e lls  in  tu m o r d estru ction . 
M acrop h ages a lso  release in te r le u k in -1 (IL -1), 
form erly  ca lled  ly m p h o c y te  a c tiv a tin g  factor 
(L A F ), w h ic h  causes p ro lifera tio n  o f T -c e lls . 
C h e m o ta c t ic  fa c to rs  lib e r a te d  by  T -c e lls  a t­
tr a c t  m a c r o p h a g e s  to  th e  so u r c e  o f  th e  in ­
f la m m a t o r y  r e s p o n s e ;  s u b s e q u e n t ly  th e s e  
m acrop h ages are im m o b iliz e d  in  the v ic in ity  
by m a cr o p h a g e - in h ib ito r y  factor (M IF), and  
th e r e a f te r  a c t iv a t e d  in  th e  p r e se n c e  o f  th e  
a n t ig e n  b y  m a c r o p h a g e - a c t iv a t in g  fa c to r  
(M A F  or in te r fe r o n ) , w h ic h  is p ro b a b ly  th e  
sa m e as M IF . 3 T h e  e n d  re su lt  is a c y to to x ic  
e ffector  c e l l ,  cap ab le  o f  k i l l in g  th e  a n tig en  or 
tu m o r  ce ll.
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TABLE 1
Products of Activated Lympocytes*
Mediators Affecting Macrophages:
Macrophage inhibitory factor (MIF) 
Macrophage activating factor (interferon-7) 
Macrophage aggregation factor 






Antibody enhancing factors 






Chemotactic augmentation factor 






‘ Adapted from Bellanti J, Rocklin R. Im m unology ill. Philadelphia, Pa: WB 
Saunders; 1985.
H u m o r a l  I m m u n e  R e s p o n s e
T h e  h u m ora l im m u n e  response is th e  sec­
o n d  m a jo r  arm  o f  th e  im m u n e  sy s tem  and  
e n c o m p a s s e s  th e  s t im u la t io n ,  p r o d u c t io n ,  
an d  lib e r a tio n  o f  a n t ib o d ie s  to  sp e c if ic  a n t i­
g e n s . T h is  ch a rg e  is u n d er ta k en  by  th e  B -  
ly m p h o c y te . T h is  c e ll , after o r ig in a tin g  and  
p resu m a b ly  a tta in in g  im m u n o co m p eten ce  in 
th e  b o n e  m a r r o w , r e s id e s  in  th e  g e r m in a l  
c e n te r s  o f  p e r ip h e r a l ly m p h o id  s i t e s ,  u l t i ­
m a te ly  m a t u r in g  to  b e c o m e  th e  a n t ib o d y -  
secre tin g  p lasm a c e l l .75 F ive m ajor classes o f  
im m u n o g lo b u lin s  are recogn ized : Ig G , Ig A , 
Ig M , I g D , and IgE . T h ese  are d ifferen tiab le  
on  the basis o f  th e  heavy p e p tid e  ch a in  char­
a c ter istic s , bu t a lso on  other param eters, such  
as th e ir  p resen ce  in  ex tern a l secre t io n s  and  
a b ility  to  traverse the p lacen ta .
C i r c u l a t i n g  a n t i b o d i e s  r e a c t i n g  w i t h  
t u m o r -r e la t e d  a n t i g e n s  a r e  d e t e c t a b le  in  
m a n y  t u m o r  s y s t e m s . 67'79 T h e  i m m u ­
n o g lo b u lin s  are p red o m in a te ly  Ig G  and IgM , 
In th e  p resen ce  o f  c o m p le m e n t , Ig M  a n ti­
b o d ie s  m a y  b e  c y t o t o x ic  in  v i t r o  to  tu m o r  
c e l ls .  I g G , o n  th e  o th e r  h a n d , a p p ea rs  to  
m ed iate  c y to to x ic ity  b y  fa c ilita t in g  su ch  cells 
as m acrophages or natural k ille r  (N K )  ce lls  to 
recogn ize  and destroy  th e  tu m o r  ta rg et. T his  
a n tib o d y -d ep en d en t ce ll c y to to x ic ity  (A D C C ) 
is in d e p e n d e n t  o f  c o m p l e m e n t .  In  c o m ­
p arison  w ith  c e ll -m e d ia te d  im m u n it y ,  such  
an tib od y  c y to to x ic ity  is prob ab ly  o f  secon d ­
ary im p o r ta n ce  in  th e  d e fe n se  a g a in s t  so lid  
tum ors.
T h e  I m m u n o l o g i c a l  
R e s p o n s e  i n  I n t r i n s i c  
G l i o m a
I m m u n o l o g i c a l  P r i v i l e g e
M ile s t o n e  w o r k  o f  M e d a w a r 45 d e m o n ­
strated th e  lack  o f  im m u n e  rejection  o f  a for­
e ig n  sk in  graft tran sp lan ted  to  the brain  o f  an 
u n rela ted  in d iv id u a l , as c o m p a red  to  rejec­
tion  by  th e  sk in  rec ip ien t s ite  in  th e  sam e in ­
d iv id u a l. In terest grew  regard in g  th e  concept 
o f  th e  brain as an im m u n o lo g ic a lly  p r iv ileg ed  
site . R ationale  for th e  co n cep t w as sup ported  
by t h e  w e l l - k n o w n  a b s e n c e  o f  c e r e b r a l  
ly m p h a tic  d ra in age  an d  th e  p resen ce  o f  the  
b lo o d -b ra in  b arrier. S u ch  id eas h a v e  fu rth er  
b een  su b s ta n tia te d  b y  th e  w o rk  o f  M u rp h y  
and S tu rm , 51 G reen , 29 and o th e r s . 31,49
M u ch  data have sin ce  b een  p resen ted  to  re­
fu te  th e  c o n c e p t. N e o p la s t ic  p ro cesses d e m ­
onstrate p erm eab ility  o f  th e  b lo o d -b ra in  bar­
rier d u r in g  rad io iso top ic  brain  sca n n in g  and 
electron  m icroscop ic  e x a m in a tio n .66 In  ad d i­
tion , brain stru cture en h a n cem en t fo llo w in g  
io d in a ted  co n tra st u se  in  c o m p u te r iz e d  to ­
m o g r a p h y  (C T ) a n d  m o r e  r e c e n t ly  g a d o -  
l in iu m -D T P A  in  m a g n e t ic  reson an ce  im a g ­
in g  (M R I) is a m a n ife s ta t io n  o f  b lo o d -b r a in  
barrier com p rom ise  in  g lio m a  p a tie n ts . C el­
lu lar in filtrates in  g lio m a  (see p a g e  4 6 )  is ev i­
d en ce  th a t e ffec to r  c e lls  o f  sy s te m ic  o r ig in
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Any cell type
F ig u re  3 , C eil interactions in the generation o f cytotoxic T-lyphocytes ( C T L ), A  
C T L  requires a t least two signals fo r  functional m aturity. The f ir s t  signal is a  
class I antigen on the allogeneic ( or tumor) cell, the second signal, an activating  
lyfnphokine (e.g, interleukin-2) supplied by the helper T-cell. The helper T-cell 
itself requires appropriate stimulation for differentiation from an allogeneic de­
ndritic cell bearing appropriate class II antigen on its cell surface.
Wirli permission from Chirk WR. Tin- lixfwiuidiUil l :numLitium of iWmArn . New York. NY:
John Wiley ami Sons: 19H6,
can en ter th e  b ra in . E x p er im en ta l a lle rg ic  e n ­
c e p h a lit is  (E A E ) can b e  in d u c e d  d ir e c t ly  by  
the p assive transfer o f  c e l l s . 57
T h ere fo re , th e  p r e m ise  o f  th e  b ra in  as an 
anatom ic s ite  o f  partia l p r iv ile g e  is m ore ap ­
p ro p ria te . I t  ap p ears th a t  th e  d is r u p t io n  o f  
in teg r ity  o f  th e  b lo o d -b ra in  barrier, th rou gh  
n eop lastic , tra u m a tic , or in fla m m a to ry  p roc­
esses fa c ilita tes  th is  loss o f  im m u n e  p r iv ileg e .
G e n e r a l  I m m u n o c o m p e t e n c e  in  
th e  P a t i e n t  H a r b o r i n g  G l i o m a
Im m u n o lo g ic a l rea ctiv ity  is a ltered  in  p a ­
tien ts h a rb o r in g  m a lig n a n c y . 25 T h e y  e x h ib it  
a reduced ca p a c ity  to d e v e lo p  d elayed  c u ta n e ­
ous h y p e r s e n s it iv ity  r e a c t io n s  to  m ic r o b ia l
a n t ig e n s , 10 and  to  d e v e lo p  sen s itiv ity  to  new  
a n t ig e n s  s u c h  as d in i t r o c h lo r o b e n z e n e . 14 
B ro a d  s u p p r e s s io n  o f  h o s t  im m u n o c o m p e ­
te n c e  o ccu rs in  p a t ie n ts  h a rb o r in g  prim ary  
m a lig n a n t  brain  l e s io n s . 13 T h e  d efect is a t­
tr ib u ta b le , at lea st in  part, to  an im p airm en t  
in  T -c e ll fu n c t io n . T h ese  a lterations m ay be 
th e  r e su lt  o f  im p a ir e d  a c t iv a t io n  p rocesses  
n e c e s s a r y  fo r  s u c c e s s f u l  T - c e l l  m e d ia te d  
c y t o t o x ic i t y ,  or q u a n t i ta t iv e  an d /or q u a lita ­
t iv e  d efects  in  T -c e ll  su b p o p u la tio n s .24
R o sz m a n  e t  a l64 h a v e  sh o w n  the in ferior  
p r o d u c t io n  o f  in t e r le u k in -2 in  ly m p h o c y te s  
o f  p a t i e n t s  h a r b o r in g  m a l ig n a n t  g l io m a s ,  
s u g g e s t in g  t h a t  T - h e lp e r  c e l l  fu n c t io n  in 
th ese  p a tie n ts  m ay be su sp ec t. T h is  decreased  
a b ility  for th e  T -c e ll  to  a id  in  th e  p rodu ction
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o f  a n t ib o d y  fr o m  B - c e l l s  h as b e e n  d e m o n ­
strated in  v itro . A n  actual 2 5 -3 0 %  d im in u ­
tio n  in  th e  n u m b e r  o f  c ir c u la t in g  T -h e lp er  
cells in  these p a tien ts  has b een  sh ow n . Sup­
pressor c e ll fu n c t io n  in  th e s e  p a t ie n ts  is not 
in  i t s e l f  in creased ; th u s , th e  m ech a n ism  for 
th is im m u n osu p p ression  is n o t d irectly  relat­
ed  to  T -s u p p r e s s o r  in f lu e n c e s  on  T -h e lp e r  
c e lls .62
W h ile  m u c h  e v id e n c e  su p p o r ts  th e  d e ­
creased n u m b er and fu n ctio n  o f  the T -h elp er  
s u b p o p u la t io n  o f  ly m p h o c y te s  in  p a t ie n ts  
h arb orin g  g lio m a s , th e  ex a c t m e c h a n ism  o f  
th is d ysfu n ction  and the p o ss ib ility  o f  any fu­
ture therapeutic  in terven tion  are yet to  be d e­
term ined . O n e o f  th e  central issues in  im m u ­
noth erap y  to d a y  is th e  p u r s u it  o f  a g e n ts  to  
stim u la te  the im m u n e  sy stem  in  an  a ttem p t  
to  overcom e th is in h eren t im m u n o d efic ien cy  
in  p atien ts harboring  g lio m a .
C e l lu la r  I n f i l t r a t i o n  i n  G l io m a
T h e p resen ce  o f  ly m p h o id  c e llu la r  in f i l ­
trates associa ted  w ith  g lio m a s  was first appre­
ciated  by B ertrand  and  M an n en  in  I 9 6 0 5 and  
s u b s e q u e n t ly  in  1 9 7 1  b y  R id le y  a n d  C a v ­
a n a u g h ,60 w h o  h y p o th es ized  the sign ifican ce  
o f  such in filtra tes as b e in g  th e  m an ifesta tion  
o f  a p o ss ib le  h o st-m ed ia ted  im m u n e  response  
to  th e  C N S  tu m o r . M o n o n u c lea r  in filtra te s  
have b een  d em on strated  in  th e  p arenchym a o f  
g l ia l  tu m o rs in  3 0 -6 0 %  o f  p a tie n ts  c ite d  in  
th e  l i t e r a t u r e . 55-72 V o n  H a n w h e r  e t a l , 72 
u s in g  m o n o c lo n a l  a n t i b o d ie s  a n d  im m u -  
n o p ero x id a se  m e th o d o lo g ie s ,  d em o n stra ted  
an in  s itu  id en tifica tio n  and  characterization  
o f  ly m p h o cy tes w ith in  m on on u clear  ce ll p o p ­
u la tion s in filtra tin g  b oth  h u m an  g lio m a  and  
n o n g lia l prim ary C N S  neop lasm s. T h is  stu d y  
in d ic a te d  a te n ta t iv e  p r e d o m in a n c e  o f  su p ­
p r e s s o r /c y to t o x ic  ( C D 8 + ) ly m p h o id  s u b ­
p op u lation s in v a d in g  the tu m o r parenchym a. 
H o w ev er , it  is o n ly  a ssu m ed  that th e  patterns  
o f  h e tero g en eo u s  p h e n o ty p ic  ly m p h o id  ex ­
pression  revealed in  th is  s tu d y  w o u ld  approx­
im a te  th e  d is tr ib u t io n  o f  var iou s ly m p h o id  
su b p op u lation s.
G o o d  ex p er im en ta l ev id en ce  d em on strates  
th at tu m o r - in f ilt r a t in g  T -c e l ls  p la y  an in te ­
gral role in  th e  reg u la tio n  o f  in o cu la ted  syn ­
g en e ic  tu m or ce il g r o w th .70 D e sp ite  th is , the  
precise m ech an ism s by  w h ic h  T -c e lls  are at­
tracted  to  th e  tu m o r  and  th e ir  a c t iv ity  co n ­
tr o l le d  are y e t  to  b e  u n d e r s t o o d . A s p r e ­
v io u s ly  d e s c r ib e d ,  c h e m o t a c t ic  fa c to r s  for  
ly m p h o c y te s  are s o lu b le  fa c to r s  th a t have  
b een  iso la te d  fro m  s i te s  o f  in f i l tr a t io n  o f  T -  
ce lls . O n e  such  e n t ity , ly m p h o c y te  m ig ra tio n  
factor (LM F), has b een  s tu d ied  k in e t ic a lly  in  
a g liosarcom a rat tu m o r  m o d e l and  has b een  
sh o w n  to  corre la te  to  th e  a m o u n t o f  T -c e l l  
in filtra te  observed  in  th e  tu m o r , su g g e s tin g  
th a t a t le a s t  so m e  o f  th e  n orm al m o d u la to r s  
o f  the im m u n e  response are p resen t and fu n c­
t io n a l in  th e  n e o p la s t ic  t i s s u e .77 A  su b s ta n ­
tia l b od y  o f  literature p resen ts c o n f l ic t in g  in ­
s i g h t s  r e g a r d in g  t h e  r e la t io n s h i p  o f  t h is  
m o n o n u c lea r  in f il tr a te  to  th e  c lin ic a l co u rse  
o f  g lia l  tu m ors: m a lig n a n t  b eh a v io r , tu m o r  
b u rd en , h is to lo g ic a l c e l l  ty p e s , and  p a t ie n t  
su rv iva l. 12’69
T h e sig n ifica n ce  o f  N K  in filtra tes  in  g l io ­
m as rem ains an en ig m a . W h ile  there is a b u n ­
dant in form ation  ab ou t th e  p h en o ty p ic  char­
a c te r is t ic s  o f  th e  ly m p h o c y te s  in f i l t r a t in g  
g lio m a s, non e is focu sed  on  the N K  c e ll . R e ­
c e n t ly , V a q u ero  et a l71 d e m o n o s tr a te d  N K  
cells in  at least 40%  o f  th e  g lio b la s to m a s  in  
th e ir  s tu d y  g r o u p  o f  2 5  p a t ie n ts .  H o w e v e r ,  
th e  m ere  p resen ce  o f  N K  c e lls  in  the tu m o r  
d id  n ot seem  to correlate w ith  in creased  sur­
v iv a l t im e . T h e  N K  c e l l ,  w ith  it s  in h e r e n t  
a n titu m o r  c a p a b ility , is  a c a n d id a te  fo r  im -  
m u n oth erap eu tic  m a n ip u la tio n .
S u p p r e s s iv e  F a c to r s
D e fe c t iv e  c e ll -m e d ia te d  im m u n ity  a t  p e ­
ripheral s ites  and  in  th e  tu m or it s e lf  has b een  
a ttr ib u ted , at least in  part, to  th e  p ro d u c tio n  
o f  im m u n o su p p r e s s iv e  p e p t id e s  b y  th e  n eo ­
p la stic  e lem en ts . T h e  su p ern atan t o f  g lio m a  
c u ltu r e d  c e l l  l in e s  e x h ib i t s  s u p p r e s s io n  o f  
th y m o c y te  p r o life r a t io n  an d  in t e r le u k in -2 - 
in d u ced  grow th  o f  T -c e ll  c lo n es . A u to lo g o u s  
as w e ll as h o m o lo g o u s  ly m p h o c y te  a c tiv ity  is
Immunology and Immunotherapy of Intrinsic Glial Tumors 47
suppressib le  b y  sera o b ta in ed  from  th ese  pa­
t ie n ts .3a In  p a tie n ts  fo llo w e d  p o sto p era tiv e ly  
after ra d ica l tu m o r  r e s e c t io n  th e  su p p r e sso r  
a c t iv ity  is  l o s t ,  o n ly  to  r e a p p e a r  p r io r  to  
c lin ic a l r e c u r r e n c e . 11  R o s z m a n  e t  a l6? o b ­
served th a t th is  g lia l-d e r iv e d  su p p ressiv e  fac­
tor is e ffec tiv e  o n ly  d u r in g  th e  in it ia l  even ts  
o f ly m p h o cy te  a c tiv a tio n . T h e  2 5 ,0 0 0  m o le c ­
ular w e ig h t  (M W ) fa c to r  se e m s  to  su p p ress  
T -c e l l - c y c l in g  c a p a b il i t y  fo l lo w in g  s t im u la ­
tion . H y p o th e t ic a l ly , th is  im p a ired  im m u n e  
function  m a y  be a ttr ib u ta b le  to  a ltera tio n s in  
the m o le c u la r  e v e n ts  in  n o rm a l ly m p h o c y te  
d if fe r e n t ia t io n  a n d  g r o w th . T h e  fa cto r  a p ­
p e a r s  to  d i f f e r  f r o m  t h e  la r g e r  g l y c o -  
sa m in og lycan  m o ie ty  p r e v io u s ly  d escr ib ed  by  
G ately  et a l , 27 w h ic h  appears to  fu n c t io n  by  
p ro tectin g  th e  tu m o r  c e ll  from  c e ll-m e d ia te d  
c y to to x ic ity .
W r a n n  e t  a l76 r e c e n t ly  p u r if ie d  a g l i o ­
b la s to m a -d e r iv e d  T - c e l l  su p p r e s s iv e  factor  
(G -T sF ) th a t  e x h ib i t s  su p p r e s s iv e  e ffe c ts  o n  
in te r le u k in -2 -d e p e n d e n t T -c e ll  g r o w th . T h is  
factor s u b s e q u e n t ly  h as b een  se q u e n c e d  and  
fou n d  to  h a v e  c o n s id e r a b le  h o m o lo g y  w ith  
tr a n s fo r m in g  g r o w t h  fa c to r  (3 (T G F -(3 ) . Iy 
T G F-fS has b e e n  d e m o n s tr a te d  to  retard  th e  
gro w th  o f  a v a r ie ty  o f  tr a n s fo rm ed  an d  n o r­
m al cells an d  a lso  to  in h ib it  th e  g en era tio n  o f  
c y to to x ic  ly m p h o c y te s  (C T L ) and  a c t iv a te d  
N K  c e l l s .  T h u s ,  i t  a p p e a r s  th a t  s e v e r a l o f  
these p e p tid e s  b e lo n g  to  a p ro te in  fa m ily  th at  
exh ib its a w id e  b io lo g ic a l a c tiv ity  c o n tr o llin g  
the d ifferen tia tio n  and  g r o w th  o f  variou s ce il 
typ es . I t  n a tu r a lly  fo l lo w s  th a t  th e  g l ia l  tu ­
m or ce lls  p o ssess  c a p a b ilit ie s  o f  ex p ress in g  a 
w id e  v a r i e t y  o f  i m m u n o m o d u l a t o r y  
substances.
Y o sh id a  e t  a lB() d em o n s tr a te d  th e  q u a lita ­
tiv e  d e fe c t  in  p e r ip h e r a l b lo o d  ly m p h o c y te s  
o f p a tien ts  h a rb o rin g  m a lig n a n t  brain  tum ors  
(g liom as an d  m e ta s ta tic  le s io n s) th a t in h ib its  
capacity to  p ro d u ce  in te r le u k in -2 . In  so m e o f  
their p a tie n ts , th e  d e fec ts  in  in te r le u k in -2  ac­
t iv ity  w ere  c o r r e la te d  to  c l in ic a l  s ta g e . T h is  
stu d y  has s u g g e s te d  th a t th e  im m u n o d e f i­
ciencies seen  in  su ch  p a t ie n ts  m ay  b e at least 
partially  a ttr ib u ta b le  to  the im p a ired  p rod u c­
tion  o f  in te r lu e k in -2 . W h e n  ex p o sed  to  su ffi­
c ie n t  a m o u n t s  o f  in t e r l e u k i n - 2 , t h e s e  p e ­
ripheral b lo o d  ly m p h o c y te s  w ere  in d u ced  to  
e x h ib it  c y to to x ic ity  to  g lio m a  tu m o r  ce lls .
C l i n i c a l  A p p l i c a t i o n  o f  
M o n o c l o n a l  A n t i b o d i e s
O n e  approach  to  u s in g  im m u n e  sy s tem  ca­
p a b i l i t i e s  a g a i n s t  g l i o m a  is  to  u s e  d ia g -  
n o stica lly  a sp e c if ic  g lio m a -a s so c ia te d  a n tig e n  
to d ifferen tia te  th e  tu m o r  from  n orm al tissu e  
and th en  to  m o u n t  a sp ec ific  th era p eu tic  im ­
m u n e  resp on se  to  th e  a n t ig e n . In it ia lly , p o ly ­
c lo n a l  sera  w e r e  u s e d  to  se a r c h  fo r  tu m o r  
a n t ig e n s ;  t h e s e  sera  w e r e  d e v e lo p e d  fro m  
e ith er  p a tien ts  h arb orin g  g lio m a s  or from  an ­
im a ls  in o c u l a t e d  w i t h  g l i a l  t u m o r s . 17'21 
P o ly c lo n a l an tisera  w ere cu m b erso m e  to e m ­
p lo y , r e q u ir in g  e x te n s iv e  a d so r p t io n  to  re­
m o v e  n o n tu m o r -r e la te d  a n t ib o d ie s .  T h e  a d ­
v e n t  o f  m o n o c l o n a l  a n t i b o d i e s  ( M A B )  
p ro d u ced  by th e  h y b r id o m a  te c h n iq u e , e sta b ­
lish ed  by K o h ler  and  M ils te in  in  1 9 7 5 , 3f> e n ­
a b led  th e  p r o d u c t io n  o f  a la r g e  q u a n t ity  o f  
a n tib o d y  th a t w i l l  react w ith  one sp ec ifica lly  
d e fin e d  a n t ig e n ic  d e te r m in a n t , T h is  a llo w s  
id e n t if ic a tio n  and  ch aracter iza tion  o f  a n tig en s  
p resen t o n  h u m a n  n e o p la s tic  ce lls . T h e  te c h ­
n i q u e  r e q u i r e s  t h e  f u s i o n  o f  a s p e c i f i c  
a n tib o d y -se c r e t in g  sp le e n  B -c e ll  w ith  a n eo ­
p la s t ic  n o n s p e c if ic  a n t ib o d y -s e c r e t in g  m y ­
e lo m a  c e ll . T h e  resu lt is an im m o rta l c e ll lin e  
w ith  th e  cap acity  to  p ro d u ce  u n lim ite d  q u a n ­
t it ie s  o f  a sp ec ific  a n tib o d y  (F igu re  4 ) .
T u m o r - A s s o c i a t e d  A n t i g e n s
I f  su ch  an a n t ib o d y  can  d e te c t  an  a n t ig e n  
th a t is p ro d u ced  e x c lu s iv e ly  or p red o m in a te ly  
b y  th e  g l ia l  tu m o r , th e  te c h n iq u e  o ffers th e  
p o s s ib le  u se  o f  a sc r e e n in g  te s t  su c h  as car- 
c in o em b ry o n ic  a n t ig e n  (C E A ) to d e te c t  co lo n  
cancer. T h e  lim ita t io n  o f  th is  p articu lar  a n t i­
g e n ,  h o w e v e r , has b een  its  p r e se n c e  in  n u ­
m ero u s o th e r  tu m o r  lo c a t io n s  a n d  in so m e  
n o rm a l s u b je c ts .  A n  a n a lo g o u s  p r o b le m  has  
b een  a p p a ren t in  th e  search  for a n t ig e n s  on  
g l io m a  c e l l s .  T o  d a te  n o  s p e c i f ic  a n t ig e n
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u n iq u e  to g lio m a  cells  has b e e n  is o la te d ;  
how ever, several g lio m a  an tig en s have b een  
recognized , often  w ith  prim ary rep resen ta ­
tion on gliom a cells but w ith  m inor represen­
tation  on other cellular c o n s t itu e n ts . 20 T o  
further com plicate the issue, cells o f  brain tu ­
mors have a constantly varying m u ltip rob ab le  
a n tig e n ic ity 21; ce llu lar  a n t ig e n  e x p r e s s io n  
varies w ith cell age, attem pted therapy, and  
heterogeneity o f the original cell c lon ogen e .
U sing  specific m onoclonal a n tib od ies, tw o  
groups o f antigens have been id en tified : the  
neuroectodermal or neurohem atopoietic a n ti­
gens found on the cell surface, and g lia l cy to ­
plasm ic antigens such as g lia l fibrillary ac id ic  
protein  (G FA P).44-78 N eural d if fe r e n t ia t io n  
antigens, such as neuroectoderm al-oncofetal 
or neurohem atopoietic-shared a n t ig e n s  have  
been detected w ith  M A B .7  ^ W akabayash i, e t  
al73 identified a M AB (G -22) th at recogn izes
a n eu ro ecto d erm a l a n t ig e n  ex p ressed  on  the  
su rfa ce  o f  n e o p la s t ic  c e l l s  s u c h  as g l io m a ,  
m e la n o m a , an d  lu n g  c a n c e r . T h e  fu r th er  
ch a ra cter iza tio n  o f  th is  r e c o g n iz e d  a n tig e n  
proved  to be a m em b ran e-assoc ia ted  m o lecu le  
w ith  a m o le c u la r  w e ig h t  o f  6 7  k ilo d a lto n s  
(K D ) . T h e  a n t ig e n  w as a lso  id e n t if ie d  from  
CSF iso la te s , p r e su m a b ly  b e in g  sh ed  by  th e  
n e o p la s t ic  c e l l s .  W h i l e  th e  a n t ig e n  is  e x ­
p ressed  on  n o rm a l fe ta l b ra in  t is s u e  (e ig h t  
w eek s’ g esta tio n ), i t  is n o t exp ressed  by non-  
g l i o m a t o u s  b r a in  tu m o r  o f  n o r m a l a d u lt  
b r a in  t i s s u e .  T h u s ,  t h e  p r e s e n c e  o f  th is  
reactiv ity  in  CSF or a d u lt brain tu m or tissu e  
by m eans o f  d o t - b lo t  E L ISA  te c h n iq u e  is a 
p o te n t ia l m e th o d  o f  d if fe r e n t ia t in g  g lio m a  
from  n o n g lio m a to u s tu m or tissu e .
T h e  p ro lifera t iv e  p o te n t ia l  o f  g lio m a s  has 
b een  a p rob lem atic  factor in  d e te r m in in g  the  
m ost appropriate approach to  th erap y, e sp e ­
c ia lly  in  th e  in s ta n ce  o f  lo w -g r a d e  le s io n s .  
T ech n iq u es su ch  as 3H -la b e led  th y m id in e  ati- 
t o r a d io g r a p h y  a n d  b r o m o d e o x y u r i d i n e  
(B U d R ) im m u n o h is to ch em ica l la b e lin g  have  
b e e n  e m p lo y e d  to  e s t im a t e  th e  k in e t ic  a c ­
t iv ity  o f  th e  tu m o r  as a r e f le c t io n  o f  its  in  
v iv o  p r o li f e r a t io n . D is a d v a n t a g e s  to  th e s e  
m eth od s in c lu d e  th e  n ecess ity  to  ad m in ister  
th e  la b e l p rior to  su r g ic a l r e se c t io n . M o n o ­
clonal a n tib od ies h ave b een  used  to  id en tify  a 
nuclear a n tig en  expressed  sp ec ifica lly  in  p ro­
l i f e r a t in g  c e l l s .  K i - 6 7  is s u c h  an a n t ig e n ,  
w h ic h  w a s i n i t i a l l y  r a is e d  a g a in s t  R e e c l-  
Sternberg c e lls . 28 T h e  nuclear a n tig e n  it rec­
o gn izes is p resen t o n ly  in  the G t , S , G 2 and  
M  p h a ses  o f  th e  c e l l  c y c le .  Z u b e r  e t  a l , 8S 
s tu d y in g  frozen  g l io m a  sp e c im e n s , d e m o n ­
strated  th at th e  K i-6 7  in d ex  o f  p ro lifera tin g  
c e lls  co rre la ted  w ith  th e  u su a l h is to lo g ic a l  
c la s s if ic a tio n  o f  th ese  tu m o rs ( i .e .  b ased  on  
th e  c la ss ica l m o r p h o lo g ic a l c r iter ia  su ch  as 
n u clear  m o r p h o lo g y , vascu lar  p r o life r a t io n ,  
n ecro sis , and  m ito t ic  in d e x ) . A  s ig n if ic a n t  
difference w as sh ow n  b etw een  K i-6 7  ce ll in ­
d ex  o f  anaplastic astrocytom a and lo w -g ra d e  
or b e n ig n  g lio m a . I t  m a y  h o ld  p r o m ise  as a 
r e a d ily  a v a ila b le  an d  s im p le  b io c h e m ic a l  
t e c h n iq u e  for d e te r m in in g  t h is  im p o r ta n t  
c lin ica l d is t in c t io n .
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I m m u n o t h e r a p y  o f  G l i o m a s
U n lik e  s u r g e r y , r a d io th e r a p y , or  c h e m o ­
therapy, w h ic h  h a v e  p o te n t ia lly  to x ic , l im i t ­
i n g  s i d e  e f f e c t s  o n  n o r m a l  t i s s u e ,  
im m u n oth erap y  is in h e r e n t ly  m o re  sp ec ific  in  
its se lective  k i l l in g  o f  tu m o r  ce lls .
T h e e ffec tiv en ess  o f  th e  im m u n e  sy s tem  in  
red ucing  tu m or b u rd en  m ay b e c o m p r o m ise d  
by th e  p r e s e n c e  o f  s o l u b le  tu m o r  a n t ig e n ,  
a n tig en -a n tib o d y  c o m p le x e s , and  n o n sp ec ific  
su p p ressor  h u m o r a l s u b s ta n c e s  re le a sed  by  
th e  tu m or. In  th is  c o n t e x t ,  th e  p r im e  th e o ­
retica l d ir e c t iv e s  o f  im m u n o th e r a p y  are ( I )  
a c t iv a t io n  o f  a n t i t u m o r  c e l l - m e d ia t e d  re ­
sp on ses; (2 ) a c t iv a t io n  o f  h u m o r a l c y to ly t ic  
responses; and ( 3 ) m it ig a t io n  o f  ce llu la r  su p ­
pressor responses.
O n e cen tra l th e m e  a tte n d a n t to th e  d is c u s­
sion  o f  im m u n o th e r a p y  is  th a t o f  tu m o r  bu r­
d en . L aboratory  a n d  c l in ic a l  d a ta  h a v e  e m ­
p h a s iz e d  th e  l i m i t e d  a b i l i t y  o f  th e  n o r m a l  
im m u n e  sy s te m  to  h a n d le  e x c e s s iv e  tu m o r  
lo a d ; a n a tu r a l  c o r o l l a r y  to  t h i s  is  t h a t  
c y to r e d u c t iv e  m e a su r e s  m ay  b e an a d ju v a n t  
to  im m u n o th e r a p y  in  r e d u c in g  th e  c r it ic a l  
neop lastic  m ass.
A p p lica tio n s o f  im m u n o th e r a p y  to  g lio m a  
tr ea tm en t m ay b e  c a te g o r iz e d  a c c o r d in g  to  
a c c e p te d  i m m u n o t h e r a p e u t i c  t r e a t m e n t  
m od es: a c tiv e  n o n - s p e c if ic ,  a c t iv e  s p e c if ic ,  
a d o p tiv e , p a s s iv e , an d  im m u n o r e s to r a t iv e .  
W i t h  t h e  e x c e p t i o n  o f  p a s s i v e  i m m u ­
n o th e r a p y , a ll  h a v e  b e e n ,  o r  p r e s e n t ly  are 
b e in g , ev a lu a ted  for u se  in  th e  tr e a tm e n t  o f  
g lio m a .
A c t iv e  N o n s p e c i f i c  
I m m u n o t h e r a p y
T h is  m e t h o d o lo g y  u s e s  a n t i g e n ic  s t i m ­
u la n ts  th a t are n o t  n e c e s s a r ily  s im ila r  to t u ­
m or a n tig en  b u t in crease  th e  gen era l im m u n e  
capacity o f  th e  h o s t .  T h e se  in c lu d e  a variety  
o f  m i c r o o r g a n i s m s  s u c h  a s  t h e  b a c i l l u s  
C a lm e t te -G u e r in  ( B C G ) 4K a n d  Corynebac- 
terium  p a r v u m c h e m i c a l  a g e n t s  s u c h  as 
p y r a n , a n d  i n t e r f e r o n  i n d u c e r s  s u c h  as  
p o ly a d e n y l ic - u r a d i l ic  a c id  (p o ly  A U )  and
p o ly in o s in ic - c y t id i l ic  a c id  (p o ly  I C ) . I n  th e  
la b o ra to ry  th e s e  a g e n t s  h a v e  th e  a b i l i t y  to  
m it ig a te  tu m o r  g r o w th  and  a b o r t  g r o w th  o f  
s m a ll  e s ta b lis h e d  tu m o r s .  T h e y  b o o s t  b o th  
c e l l -m e d ia te d  an d  h u m o r a l  im m u n e  r e s p o n ­
s iv e n e s s ;  th e y  a p p ea r  to  r e v e r se , a t  le a s t  in  
p a r t ,  t h e  s u p p r e s s iv e  e f f e c t s  o f  a n t i t u m o r  
a g e n ts .  O n e  c a v ea t in  th e ir  u s a g e ,  h o w e v e r ,  
is th e ir  a b ility  to  p o te n t ia te  th e  in f lu e n c e  of 
s u p p r e s s o r  T - c e l l s  a n d  s u p p r e s s o r  m a c ­
r o p h a g e s  o n  th e  i m m u n e  s y s t e m ,  t h e r e b y  
l im it in g  th e  overa ll b e n e f i t  o f  th e r a p y , In  a d ­
d it io n ,  to x ic  s y s t e m ic  a n d  lo c a l  s id e  e f f e c t s  
m a y  l im i t  e f fe c t iv e n e s s ,
A  n u m b er  o f  b io lo g ic a l  r e sp o n se  m o d if ie r s  
h ave  e m e r g e d  as p o t e n t ia l  a g e n t s  fo r  u s e  in  
p a t ie n t s  h a r b o r in g  m a l i g n a n c y .  L y m p h o ­
k in e s , as d e sc r ib e d  a b o v e ,  h a v e  b e e n  a d v o ­
cated  in  th is  regard; in te r fe r o n s  h a v e  b e e n  a d ­
m in is t e r e d  in  th e  h o p e  o f  s t i m u l a t i n g  th e  
im m u n e  s y s te m  to  r e sp o n d  to  a n t i g e n ic  t u ­
m o r  c h a lle n g e .
In terferons are s u b d iv id e d  in t o  v ir a lly  in ­
d u c e d , su c h  as le u k o c y t e - d e r iv e d  in te r fe r o n  
(a lp h a ), f ib r o b la s t -d e r iv e d  (b e t a ) ,  a n d  i m ­
m u n e  in terferon  (g a m m a ) . S o m e  p r o d u c e d  b y  
r e c o m b i n a n t - D N A  t e c h n o l o g y  a r e  u n d e r  
c lin ic a l scru t in y . I n t e r f e r o n -3 ,  th e  f ir s t  to  b e  
s tu d ied  in  g l io m a , h a s  th e  ca p a c ity  to  in h ib i t  
r e p l i c a t i o n  o f  h u m a n  g l i o m a  c e l l s  in  
v i t r o . 37,40 N a g a i  a n d  A r a i52 tr e a te d  2 0  p a ­
tien ts  in tra th eca lly  or  in tr a tu m o r a lly  and re ­
p o r ted  fa v o ra b le  r e s u l t s  in  8 o f  t h i s  s e r ie s .  
O th er  au th ors , su ch  as D u f f  e t  a l , 22 r ep o r ted  
less e n th u s ia st ic  r e su lts . I n te r fe r o n -a  a lso  d e ­
c r e a s e s  t h e  g r o w t h  o f  h u m a n  g l i o m a  in  
v it r o .53 M a h a ley  e t  a l/|2 d e sc r ib e d  a p o s i t iv e  
r e s p o n s e  in  7 o f  17  p a t i e n t s  t r e a t e d  w i t h  
in t e r fe r o n -a  e ith e r  in t r a v e n o u s ly  o r  in t r a ­
m u s c u la r ly . M o re  r e c e n t ly ,  M a h a le y  e t  a l '1 1 
rep o rted  th e ir  in i t ia l  e x p e r ie n c e  w i t h  in t e r ­
fe r o n -7 . p a t ie n t s  t r e a te d , p o s i t iv e  re ­
s p o n s e  w a s  s e e n  d e f i n i t e l y  in  o n ly  o n e  p a ­
t ie n t ,  and  s ta b iliz a t io n  for  a p er io d  o f  12  to  
86 w e e k s  w a s  s e e n  in  a n  a d d i t io n a l  t h r e e .  
T o x ic i t ie s  a sso c ia te d  w i t h  its  u s e  in c lu d e d  
h y p o te n s io n  d u r in g  in f u s io n ,  c h i l l s ,  f e v e r ,  
n a u se a , v o m i t i n g ,  a n d  e le v a t e d  l i v e r  e n ­
zy m es . T h is  p r e lim in a r y  ser ies s u g g e s t s  th a t
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fu rth er  research sh o u ld  p referen tia lly  focus on  
th e  u se  o f  in terferon-ct and -(3.
A c t i v e  S p e c i f i c  I m m u n o t h e r a p y
A c t iv e  sp e c if ic  im m u n o th e r a p y  refers to  
th e  u se  o f  sp e c if ic  im m u n iz a t io n  u s in g  su b ­
stan ces that are a n tig en ica lly  related  to prod ­
u cts o f  th e  tu m or. A  sp ec ific  a n tig e n , such  as 
tr e a te d  tu m o r  c e lls  from  th e  p a t ie n t ,  or tu ­
m or c e lls  from  an a n tig en ica lly  s im ilar  tum or  
in  a n o th er  p a t ie n t ,  m ay b e  e m p lo y e d  to  in ­
d u ce an  im m u n e  response in  th e  in d iv id u a l. 
A n tig e n ic ity  o f  tu m or ce lls  m ay b e  enhanced  
b y  re m o v in g  th e  s ia lic  a c id  c o a t in g  around  
th e  c e l ls  w ith  n eu r a m in id a se . T u m o r  c e lls ,  
k illed  b y  eith er  x-ray or ch em ica l agen ts such  
as m ito m y c in -C , have also b een  u sed  to pre­
pare c e ll- fr e e  a n t ig e n  ex tr a c ts . In  th is  fa sh ­
io n , sp e c if ic  im m u n iz a t io n  is s t im u la te d  to  
co m b a t th e  a n tig en  (in  th is  case, tu m o r  ce ll). 
C ross-reactin g  a n tig e n s , e ith er  v ira l or bacte­
ria l, m a y  be a p p lied  for th e  sam e fu n ction a l 
re sp o n se . T h e  in h e r e n t p it fa l l  in  th is  te c h ­
n iq u e is  the in d u c t io n  o f  an  a u to im m u n e  re­
sp o n s e  to  n o r m a l b r a in  b y  c r o s s - r e a c t iv ity  
w ith  c o m m o n ly  sh a red  c e l lu la r  a n t ig e n s .  
T h is  ex p er im en ta l a llerg ic  en cep h a lit is  (EA E) 
is a risk  to  be con sid ered .
T h e  c o n c e p t is n o t  n o v e l. In  I 9 6 0 ,  W .H .  
B lo o m  e t  a l7 a tte m p te d  to  in d u ce  an  im m u n e  
r e sp o n se  in  a p a t ie n t  h a rb o r in g  a g lio m a  by 
th e  s u b c u t a n e o u s  im p la n t a t io n  o f  g l io m a  
c e l l s  in t o  th e  t h ig h s .  T h e  p a t ie n t  s u b s e ­
q u e n t ly  d ie d  w ith  p a th o lo g ic a l e v id e n c e  o f  
g lio m a  in  th e  brain w ith  n o  ev id en ce  o f  im ­
m u n e  resp o n se ; in  a d d it io n , tu m o r a l spread  
in  th e  th ig h  an d  re g io n a l ly m p h  n o d es was 
e v id e n t a t au top sy .
In 1 9 7 3 , H .J .G .  B lo o m  e t a l6 u sed  irradi­
a ted  a u to lo g o u s  tu m or ce lls  in  p a tien ts  w ith  
m a lig n a n t  g lio m a s  treated  b y  radical surgery  
and  p osto p era tiv e  rad iation . T h e  resu lts  were 
d isa p p o in tin g ; there was no  sta tis tica l d iffer­
e n ce  b e tw e e n  p a t ie n ts  im m u n iz e d  w ith  the  
a u to lo g o u s  tu m o r  c e lls  an d  th o se  r ece iv in g  
su rg ery  and ra d ia tio n  th era p y  a lo n e . In  the  
m a jo r ity  o f  c a se s  in  th is  s tu d y  th e r e  w as  
c lin ica l ev id en ce  o f  tu m or recurrence, proven
h is to lo g ica lly  in  9 o f  10  p a tien ts  at autopsy. 
In  a d d it io n ,  o f  th e  p a t ie n t s  w h o  rece iv ed  
m u lt ip le  in je c t io n s  o f  ir ra d ia ted  a u to lo g o u s  
tu m or ce lls , none sh o w ed  ev id en ce  o f  p ositive  
in traderm al sk in  tests  to  in d ica te  a successful 
im m u n e  resp o n se  h ad  b e e n  m o u n te d . O ne  
p la u sib le  ex p la n a tio n  for th ese  d isa p p o in tin g  
r esu lts  w as th e  p o s s ib i l i t y  th a t tr e a tm e n t of 
th e  c e l l s  w i t h  1 5 , 0 0 0  rad s o f  r a d ia t io n  
reduced their a n tig e n ic ity .
A d o p t i v e  I m m u n o t h e r a p y
A d o p t iv e  im m u n o t h e r a p y  is  a p r o c e ss  
w hereby im m u n ity  is transferred via  ly m p h o ­
id  ce lls  or su b cellu lar  in fo rm a tio n . In itia lly , 
th is  w as a cco m p lish ed  b y  th e  transfer o f  his- 
to c o m p a tib le  ly m p h o c y te s  from  o n e  p a tien t  
to another. T h ese  carefu lly  m a tch ed  ly m p h o ­
cytes have p reven ted  tu m o r g ro w th  in  experi­
m en ta l sy s te m s . S u b s e q u e n t ly , a u to lo g o u s  
peripheral b lood  ly m p h o cy tes  w ere u tilized  as 
th e  don or so u rce , o b v ia t in g  th e  p r o b le m  o f  
h is to co m p a tib ility .
In  1 9 7 2 , T ak ak u ra  e t  a l68 f ir s t  reported  
usin g  a llo g en ic  b on e m arrow  c e ll transfusion  
or lo ca l in tra tu m o ra l in fu s io n  o f  a u to lo g o u s  
or a llo g e n ic  p er ip h era l b lo o d  ly m p h o c y te s  
after su rg ica l, rad iation , or ch em oth erap eu tic  
treatm ent o f  p a tien ts  w ith  m a lig n a n t neural 
tum ors. L en gth y  su rviva l t im e s  w ere reported  
anecdotally; th is m ay have reflected  th e  in d i­
v idu al tu m or’s natural h istory . A s no controls  
w ere in c lu d ed  in  th e  stu d y  d e s ig n , th e  study  
results w ere d ifficu lt  to  in terp ret.
S u b seq u en tly , Y o u n g  e t a l81 d irec tly  in oc­
u lated  a u to logou s ly m p h o cy tes  in to  recurrent 
g l io b la s t o m a  tu m o r  b e d s  v ia  i n d w e l l in g  
catheters or at cran io tom y. T h ese  au to logou s  
ly m p h o c y te s  w ere  is o la te d  from  p er ip h era l 
b lo o d  and p la ced  in  d ir e c t  c o n ta c t  w ith  the  
tum or cells in  an a tte m p t to  in d u ce  in  vitro  
sen sitiza tion . A ll  o f  th e  p a tien ts  in  the series 
h ad  fa ile d  c o n v e n t io n a l  th e r a p ie s .  A g a in ,  
som e rem arkable an ecd ota l ex ten d ed  survivals 
w ere n o ted  a m o n g  th e  17 p a t ie n ts  trea ted . 
N o  treatm en t-rela ted  to x ic ity  w as n oted .
T h e am algam  o f ce llu lar  im m u n o lo g y  and 
reco m b in a n t D N A  te c h n o lo g y  has en ab led
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the use o f  reco m b in a n t ly m p h o k in e s  su ch  as 
in te r le u k in -2  to  e x p a n d  s e le c t iv e  ly m p h o id  
p op u la tion s in  v itro .
In the 1 9 8 0 s , in te r e s t  was rek in d led  in  th e  
use o f  im m u n o th e r a p y  w ith  th e  d e s c r ip t io n  
o f  a new  c la ss  o f  ly m p h o id  k ille r  c e ll  cap ab le  
o f  k i l l in g  tu m o r  c e l l s  in  v i t r o . 30 W h i l e  a t ­
tem p tin g  to  iso la te  ly m p h o id  c e lls  w ith  a n t i­
tu m o r r e a c t iv ity  fr o m  tu m o r -b e a r in g  h o s t s ,  
th e  in c u b a t io n  o f  l y m p h o c y t e s  in  i n t e r ­
le u k in -2 r e su lte d  in  th e  g e n e r a t io n  o f  a c t i ­
vated  ly m p h o id  ce lls  cap ab le  o f  ly s in g  fresh , 
a u to lo g o u s , s y n g e n e ic , or a lL o g en ic  tu m o r  
c e l l s  b u t  n o t  fr e s h  n o r m a l  c e l l s . 82 T h e s e  
ly m p h o k in e -a c t iv a te d  k il le r  (L A K ) c e i l s  are 
th e  resu lt o f  in c u b a t io n  o f  p e r ip h e r a l b lo o d  
ly m p h o cy tes w ith  h ig h  d oses o f  in te r lu e k in -2 
for a period  o f  three days or lo n g er .
L A K  c e l l s  are p h e n o t y p i c a l l y  d i f f e r e n t  
from  c la ss ic  c y to t o x ic  T - ly m p h o c y te s ;  m o s t  
L A K  cells precursors h a v e  th e  surface m arkers  
L eu 4 ~  11 +  15 + .65 F u n c t io n a l  a n a ly s is  re­
veals that th e y  d iffer  from  N K  c e lls  in  th eir  
a b il ity  to  k i l l  fresh  tu m o r  c e l ls  th a t  are u n ­
affected by th e  N K  c e lls  in  m ajor  h is to c o m ­
p a tib ility  c o m p le x  (M H C ) u n restr ic ted  fash­
i o n .  B e c a u s e  l a r g e  a m o u n t s  o f  t h e s e  
re c o m b in a n t ly m p h o k in e s  can  b e p r o d u c e d ,  
im m u n o lo g ic a l reaction s can  be m a n ip u la ted  
in  v ivo  in  w a y s  n ot p r e v io u s ly  p o s s ib le .61
In itia lly , M a zu m d er  and  R o se n b e r g 43 had  
d em on stra ted  that sy s te m ic  a d m in is tr a tio n  o f  
in te r le u k in -2  and ly m p h o c y te s  a c t iv a te d  by  
IL-2 p rod u ced  ev id en ce  o f  p u lm o n a r y  tu m o r  
m e t a s t a t i c  r e g r e s s io n .  H o w e v e r ,  a d o s e -  
l i m i t in g  t o x i c i t y  o f  in t r a v e n o u s ly  a d m in ­
istered  IL -2  w as o b se r v e d  by L o tz e  e t  a l , 39 
co n sistin g  o f  fever, m a la ise , an orex ia , g a str o ­
i n t e s t i n a l  s y m p t o m s ,  a n d  w e i g h t  g a in  
th o u g h t to b e secon d ary  to  extravascu iar  flu id  
accu m u la tio n . M itc h e ll e t  a l/l7 d em o n stra ted  
that L A K  c e lls  m ay b e g en era ted  in  m a n  after  
a d m in is tr a t io n  o f  m in im a l ly  to x ic  d o se s  o f  
in t e r le u k in - 2 .  I t  a p p e a r s  t h a t  th e  im m u ­
n o m o d u la to r y  e f f e c t s  o f  i n t e r l e u k i n - 2 , a t  
least in v itr o , are very  m u c h  d e p e n d e n t  up on  
the dosage o f  th e  ly m p h o k in e  ex p o sed  to  the  
peripheral b lo o d  ly m p h o c ty e s . K edar e t  a l3'1 
reported  th a t  h ig h - d o s e  IL -2  m a y  e l i c i t  im ­
m u n o s u p p r e s s io n  m e d ia te d  b y  ly m p h o k in e -  
a c t iv a te d  k i l l e r  c e l l s  a n d  n o n s p e c i f ic  s u p ­
pressor ce lls .
I n t e r e s t  h a s  d e v e lo p e d  in  th e  p o t e n t ia l  
b e n e fit  o f  a u to lo g o u s  ce llu la r  in fu sio n s  in tra ­
th eca lly  in  th e  h o p e  o f  s t im u la t in g  a d irec t, 
in ten se  loca l im m u n e  resp on se .
T h e  k i l l in g  o f  g l io m a  ce lls  by L A K  cells  in  
v itro  w as d em o n s tr a te d  e le g a n t ly  by th e  w ork  
o f  J a c o b s  e t  a l . 32 S u b s e q u e n t ly  th i s  g r o u p  
p u b l i s h e d  p r e l im in a r y  r e s u l t s  o f  a p h a s e  1 
c lin ic a l tria l in  w h ic h  n in e  p a tien ts  w ith  m a ­
l i g n a n t  g l i o m a  w e r e  t r e a t e d  w i t h  i n t e r ­
le u k in -2  or L A K  c e l l s . 33 T h ere  w ere no s ig n s  
o f  sy s te m ic  or n eu ra l to x ic ity  fo l lo w in g  trea t­
m e n t , in d ic a t in g  th a t th ese  e le m e n ts  m ay be  
sa fe ly  a d m in is t e r e d  to  p a t ie n t s  w ith  m a l ig ­
n an t g lio m a .
T h e  s u p p r e s s iv e  e f fe c t  o f  lo c a l g l io m a  s u ­
p ern atan t has th e  ca p a c ity  to l im it  th e  fu n c ­
t io n a l r e s p o n s e  o f  in t e r l e u k i n -2  a c t iv a t e d  
ly m p h o c y t e s ;  t h u s ,  i n t u i t i v e l y ,  th e  m e t h ­
o d o lo g y  o f  a c t i v a t i n g  L A K  c e l l s  in  v i t r o  
s h o u ld  c ir c u m v e n t  th is  fa c to r . In  p o in t  o f  
fact, w h en  B o sn es  and H ir sc h b e r g 8 com p ared  
th e  a c t iv ity  o f  L A K  c e lls  o b ta in e d  fro m  p a ­
tie n ts  w ith  g l io m a  and  n orm al su b jec ts , th ey  
n o te d  s im ila r  le v e l s  o f  c y t o t o x ic i t y  in  th e  
c e lls  from  th e  tw o  g r o u p s . T h is  w a s  a s u r ­
p r is in g  f i n d i n g ,  c o n s id e r in g  th e  c o m p r o ­
m ised  sta tu s o f  ce llu la r  im m u n ity  in  g lio m a  
p a t i e n t s .  T h e r e  w a s ,  h o w e v e r ,  a m a r k e d  
red u ctio n  in  th e  n u m b er  o f  c ir c u la tin g  m o n o ­
n u c lea r  c e l l s ,  a f in d in g  su p p o r te d  b y  o th e r  
in v e s t ig a to r s .  A ls o ,  c o n c u r r e n t a d m in is tr a ­
t io n  o f  s t e r o id s , f r e q u e n t ly  u sed  in  g l io m a  
p a t ie n ts ,  l im i t s  th e  p o te n t ia l  y ie ld  o f  L A K  
c e l l s . 56 T h e y  c o n c lu d e d  th a t a lth o u g h  L A K  
c e lls  d er ived  from  a p a tie n t  w ith  g lio m a  are 
h ig h ly  c y to to x ic , th e  lo w  y ie ld  o f  L A K  ce lls  
from  th e se  p a t ie n ts  m a y  l im i t  e ff ic a c y , an d  
th a t furth er r e fin em en t o f  harvest te ch n iq u es  
sh o u ld  be a ch iev ed .
A  lo n g -te r m  fo llo w -u p  o f  a series o f  24  p a ­
t i e n t s  w i t h  r e c u r r e n t  m a l ig n a n t  g l i o m a  
trea ted  w ith  r e c o m b in a n t  IL -2  (rIL -2 ) and  
L A K  c e l l s  w a s  c a r r ie d  o u t  b y  M e r c h a n t  e t  
a l/ 16 T h e  p a tie n ts  a ll had g lio b la s to m a , w ith  
th e  e x c e p t i o n  o f  o n e  p a t i e n t  h a r b o r in g  a
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h ig h -g r a d e  o lig o d e n d r o g lio m a . A ll p a tien ts  
had in traparenchym al in jection s o f  th e  LA K  
c e lls  w ith  rIL -2  in to  th e  t is s u e  su rro u n d in g  
the tu m or ca v ity . For a p eriod  o f  three days, 
all p a tie n ts  u n d e r w e n t su b se q u e n t d a ily  in ­
jections o f  rIL-2 in to  th e  tu m or cavity  v ia  an 
O m m aya reservoir or th rou gh  th e  scalp  flap. 
T h ey  th en  received  an ad d ition a l course o f  in ­
t r a c a v i t a r y  L A K  a n d  r I L - 2  1 0  d a y s  
postop eratively . P atien ts a ll experienced  in ­
creased  in tracran ia l pressu re  (IC P ), p r e su m ­
ably secondary to  increased ed em a fo llo w in g  
L A K  cell in jection . T h e  m ed ian  t im e  for tu ­
m or recurrence was 22  m on th s; rad iographic  
fo l lo w -u p  in  t h e  p o s t o p e r a t iv e  p e r io d  r e ­
vealed  loca l recurrence or p rogress ion  in  on ly  
12 o f  the p a tien ts . A n  a d d itio n a l 10 p a tien ts  
died  w ith o u t ev id en ce o f  tu m o r  recurrence or 
w ith  tu m o r  at d is t a n t  s i t e s .  O n ly  tw o  p a ­
tien ts in  th e  series w ere rep orted ly  a liv e  and  
free o f  tum or recurrence at t im e  o f  fo llo w -u p .  
P ostm ortem  stu d ies  revealed  h is to lo g ic a l e v i­
d en ce o f  e x te n s iv e  n e c r o s is , rea c tiv e  a stro ­
cytes, and g lio m a  c e lls  at th e  s ite  o f  L A K  in ­
je c t io n . T h e  a u th o r s  c o n c lu d e d  th a t  th is
F ig u re  5 . The current methodology fo r  instilla tion  of 
adoptive immunotherapeutic agents a t  our institution. Spe­
cia lly  designed silicone catheters ivith  holes a t  variable  
lengths along the shaft enable delivery o f predetermined a l­
iquots of reactants to the tumor bed a n d  margins (A) .  The 
flanges are compatible w ith standard syringe systems for 
injection. A  collar sutured to the scalp permits secure f ix a ­
tion of the catheter. These catheters are stereotactically 
placed utilizing either C T  or M R I guidance in an array 
to facilitate delivery o f L A K  cells or lymphokines through- 
•tt the viable tumor an d  tumor margins.
therapy o ffered  n o  a d v a n ta g e  o v e r  co n v en ­
tional treatm en t d u e  to  th e  in f iltr a tiv e  nature 
o f  these lesion s.
E x p er ien ce  a t our in s t i t u t io n  w ith  LA K  
cell im p lan ts has fac ilita ted  th e  d ev e lo p m en t  
o f  s p e c ia lly  d e s ig n e d  c a th e t e r s .  T h e s e  are 
used in  stereotactic  array im p la n ta t io n  at pre­
d e term in ed  p o in ts  at or b e y o n d  th e  tum or  
m a r g in s  to  in c o r p o r a te  th e  le a d in g  e d g e . 
T h is  m e th o d  tak es a d v a n ta g e  o f  c o n te m p o ­
rary im a g in g  to d e liver  im m u n o lo g ic a lly  ac­
tive  e le m e n ts  to  a s tr u c tu r a lly  d e f in e d  area 
rath er  th a n  r e ly in g  o n  c o n c e p t u a l ly  b lin d  
op en  m e th o d s  for c o m p o n e n t  d e liv e r y . The  
catheters are flan ged  and are co m p a tib le  w ith  
standard lu e r - lo c k  sy r in g e  s y s te m s  to  a llow  
repeat in jections o f  L A K  ce lls  or in ter leu k in  
fo llow in g  su rgica l p la cem en t (F ig u re  5). The 
ca th e ter s  are p la c e d  u s in g  im a g e -d ir e c te d  
stereotaxy (C T  or M R I) u n d er lo ca l anesthe­
sia; th is enables precise lo c a liz a t io n  based on 
radiographic im a g in g  n o t o b ta in a b le  v ia  open  
cran io tom y , w ith  th e  a d d it io n a l b e n e f it  o f  
catheters p laced  at th e  m arg in s d e liv e r in g  the 
L A K  cells to p o ten tia l reg ion s o f  in filtra tion . 
In je c t io n  o f  im m u n o th e r a p e u t ic  a g e n ts  is 
perform ed at regular in tervals p ostop eratively  
at th e  b e d s id e . T h e  c a th e te r s  are  th e n  re­
m o v ed  a s e p t ic a l ly  at th e  b e d s id e  a fter  the 
trea tm en t cou rse  is c o m p le te .  T h is  m eth od  
has proven sim p le  and safe, is a ssocia ted  w ith  
m in im al p a tien t m o rb id ity , and o b v ia tes  the 
a tte n d a n t r isk s  o f  g e n e r a l a n e s t h e s ia .  To  
d ate , use o f  a c tiv a te d  c e lls  or c e ll  p rod u cts  
(lym p h ok in es) has n ot b een  sh ow n  to  s ig n ifi­
can tly  a lter su rv iv a l in  p a t ie n ts  w it h  m a lig ­
nant g liom as.
R e s to r a t i v e  I m m u n o t h e r a p y
Im m u n o resto ra tio n  o f  d e p ressed  ce llu lar  
im m u n ity  m ay be u n d erta k en  w ith  ag en ts  
s u c h  as t h y m ic  h o r m o n e s , 18 o f  w h ic h  a 
num ber o f  fractions have b een  iso la ted . T hese  
agents have th e  capacity  to restore depressed  
T -ce ll su b p op u la tion s to  norm al le v e ls , both  
from  a q u a n t ita t iv e  an d  q u a l i t a t iv e  s ta n d ­
p o in t . O th er  su b sta n ces , su ch  as C y to x a n , 
have th e  a b ility  to  in h ib it  s p e c if ic a l ly  sup-
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h ig h -g r a d e  o l ig o d e n d r o g lio m a . A ll p a tien ts  
had in trap aren ch ym al in jection s o f  th e  LA K  
c e lls  w it h  rIL -2  in to  th e  t is su e  su rrou n d in g  
th e  tu m or ca v ity . For a p eriod  o f  three days, 
a ll p a t ie n ts  u n d e r w e n t su b se q u e n t d a ily  in ­
jection s o f  rIL-2 in to  the tu m or cavity  v ia  an 
O m m aya  reservoir or th rou gh  the sca lp  flap. 
T h ey  th en  received  an ad d ition a l course o f  in ­
t r a c a v i t a r y  L A K  a n d  r I L - 2  1 0  d a y s  
p ostop eratively . P atien ts a ll experienced  in ­
creased  in tracran ia l pressu re  (IC P ), p re su m ­
ably  secondary to  increased edem a fo llo w in g  
L A K  c e ll in jection . T h e m ed ia n  t im e  for tu ­
m or recurrence was 22  m on th s; radiographic  
fo l lo w -u p  in  th e  p o s to p e r a t iv e  p e r io d  re­
vealed local recurrence or p rogression  in  on ly  
12 o f  th e  p a tien ts . A n  a d d itio n a l 10 p atien ts  
died  w ith o u t ev id en ce  o f  tu m o r recurrence or 
w ith  tu m o r  a t d is ta n t  s i t e s .  O n ly  tw o  p a ­
tien ts in  the series w ere reported ly  a live  and  
free o f  tu m or recurrence at t im e  o f  fo llo w -u p . 
P ostm ortem  stu d ies revealed h is to lo g ica l e v i­
d en ce o f  e x te n s iv e  n e c r o s is , reactive  a stro ­
cytes, and  g lio m a  ce lls  at th e  site  o f  L A K  in ­
je c t io n . T h e  a u th o r s  c o n c lu d e d  th a t  th is
F ig u re  5 . The current methodology for instillation of 
adoptive immunotherapeittk agents a t our institution. Spe­
cially designed silicone catheters w ith  holes a t variable 
lengths along the shaft enable delivery of predetermined a l­
iquots o f reactants to the tumor bed an d  margins (A).  The 
flanges are compatible w ith standard syringe systems for 
injection. A  collar sutured to the scalp permits secure f ix a ­
tion of the catheter. These catheters are stereotactically 
placed utilizing either C T  or M R I guidance in an array 
to facilitate delivery o f L A K  cells or lymphokines through­
out the viable tumor and tumor margins.
th erap y  offered  n o  a d v a n ta g e  o v er  co n v en ­
tional treatm ent due to  th e  in filtra tiv e  nature 
o f  these lesions.
E x p er ien ce  at our in s t i t u t io n  w ith  LAK  
cell im p lan ts has fa c ilita ted  the d eve lop m en t 
o f  s p e c ia lly  d e s ig n e d  c a th e t e r s .  T h e s e  are 
used in  stereotactic  array im p la n ta tio n  at pre­
d e term in ed  p o in ts  at or b e y o n d  th e  tum or  
m a r g in s  to  in c o r p o r a te  th e  le a d in g  ed g e . 
T h is  m e th o d  takes a d v a n ta g e  o f  c o n te m p o ­
rary im a g in g  to d eliver  im m u n o lo g ic a lly  ac­
t iv e  e le m e n ts  to  a s tr u c tu r a lly  d e f in e d  area 
ra th er  th an  r e ly in g  o n  c o n c e p t u a l ly  b lin d  
o p en  m eth o d s for c o m p o n e n t  d e liv e r y . The 
catheters are flanged  and  are co m p a tib le  w ith  
stan dard  lu e r - lo c k  sy r in g e  s y s te m s  to  a llow  
repeat in jections o f  L A K  ce lls  or in terleu k in  
fo llo w in g  surgica l p la cem en t (F igu re  5 ). The 
c a th e te r s  are p la c e d  u s in g  im a g e -d ir e c te d  
stereotaxy (C T  or M R I) u n d er lo ca l anesthe­
sia; th is enables precise  lo c a liz a t io n  based on 
radiographic im a g in g  n o t o b ta in a b le  via open 
c ra n io to m y , w ith  th e  a d d it io n a l b e n e fit  of 
catheters p laced  at the m a rg in s d e liv e r in g  the 
L A K  cells to p o ten tia l reg io n s o f  in filtra tion . 
In je c t io n  o f  im m u n o th e r a p e u t ic  a g e n ts  is 
perform ed at regular in terva ls p ostop eratively  
at th e  b e d s id e . T h e  c a th e te r s  are  th e n  re­
m o v e d  a s e p t ic a l ly  at th e  b e d s id e  a fter  the 
trea tm en t cou rse is c o m p le te . T h is  m eth od  
has proven sim p le  and safe, is associa ted  w ith  
m in im a l p a tien t m o rb id ity , and o b v ia tes  the 
a tte n d a n t  r isk s  o f  g e n e r a l a n e s t h e s ia .  To 
d a te , u se  o f  a c tiv a ted  c e lls  or c e l l  products  
(lym p h ok in es) has not been  sh o w n  to s ig n ifi­
ca n tly  a lter su rv iv a l in  p a t ie n ts  w ith  m a lig ­
nant g liom as.
R e s to r a t i v e  I m m u n o t h e r a p y
Im m u n o resto ra tio n  o f  d ep ressed  ce llu lar  
im m u n ity  m ay be u n d erta k en  w ith  agents  
s u c h  as t h y m ic  h o r m o n e s , 18 o f  w h ic h  a 
num ber o f  fractions have b een  iso la ted . These 
agents have the capacity  to restore depressed  
T -c e ll su b popu lations to  norm al le v e ls , both  
from  a q u a n t ita t iv e  a n d  q u a l i t a t iv e  s ta n d ­
p o in t . O th er  su b s ta n ces , su ch  as C ytoxan , 
have the a b ility  to  in h ib it  sp e c if ic a l ly  sup­
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pressor c e l l s ,  th e r e b y  e n h a n c in g  o v e r a ll im ­
m u n e  s y s t e m  a c t i v i t y .  T o  d a te  th e r e  is  n o  
su bstantia l c lin ic a l ev id en ce  for th e  efficacy  o f  
th is  th e r a p y  in  t h e  s p e c i f i c  t r e a t m e n t  o f  
g liom a.
P a s s i v e  I m m u n o t h e r a p y
I d e n t if ic a t io n  o f  a tu m o r -s p e c if ic  a n t ig e n  
w ou ld  a llo w  th e u se  o f  h y b r id o m a  te c h n o lo g y  
to  d e v e lo p  a n t i tu m o r  a n t ib o d ie s  to  m e d ia te  
a n tib o d y -d ep en d en t, c e ll-m e d ia te d  k i l l in g  o f  
selected  g lio m a  c e lls .  T h is  m o d e  o f  trea tm en t  
has b een  s h o w n  to  b e  e f f e c t iv e  in  r o d e n ts  
against d isp ersed  tu m o r s , p a r ticu la r ly  le u k e ­
m ia. It d o es  carry th e  in h eren t d an ger  o f  th e  
creation o f  b lo c k in g  factors (a n t ig e n -a n t ib o d y  
com p lexes) th at m a y  o ccu r in  v iv o , w ith  c o n ­
seq u en t e n h a n c e m e n t  o f  tu m o r  g r o w th . In  
a d d it io n  to  A D C C ,  c o n j u g a t i o n  o f  M A B  
w ith  c y t o t o x ic  c h e m ic a ls  or  r a d io n u c l id e s  
m ay offer a n o th er  p o te n t ia l aven u e  by w h ich  
to d irect a sp e c if ic  c y to to x ic  resp on se a g a in st  
g lio m a  c e l l s ,  s h o u ld  s p e c i f ic  a n t ig e n s  b e  
id en tified  (T a b le  2 ).
F u t u r e  P e r s p e c t i v e s  a n d  
A p p r o a c h e s  t o  
I m m u n o t h e r a p y
I f  im m u n o th e r a p y  is to  be used  to  its m a x ­
im u m  p o te n t ia l  in  tr e a t in g  m a lig n a n t  d i s ­
e a se , c l a r i f i c a t i o n  o f  f u n d a m e n t a l  i s s u e s  
related  to  im m u n e  m e c h a n is m s  in  g l io m a -  
b earing  p a t ie n t s  m u s t  be r e a liz e d . H is to r ­
ica lly , th e  p ro v en  b en efic ia l effects o f  im m u ­
n oth erap y  in  th e  tr e a tm e n t  or p r e v e n t io n  o f  
in fectious d isea se  h ave been  b ased  o n  th e  d e ­
v e lo p m e n t  o f  a s p e c i f i c  i m m u n i t y .  T h is  
should  be an a c tiv e  area o f  fu tu re  th erap eu tic  
e x p lo r a t io n , a n d  th e  d e f i n i t i o n  o f  tu m o r -  
sp ec ific  a n t ig e n s  is c e n tr a l to  th e  ta sk . B y  
a n a logy  w it h  o th e r  m a m m a lia n  m o d e ls  and  
ev id en ce  from  p r e v io u s ly  d is c u s s e d  w o r k , it  
is lik e ly  th a t tu m o r -sp e c if ic  or h ig h ly  tu m o r-  
a sso c ia te d  a n t i g e n s  d o  e x i s t .  M o n o c lo n a l  
a n t ib o d ie s  p r o d u c e d  b y  h y b r id o m a  m e t h ­
o d o logy  are fa c i li ta t in g  the search .
A n o th er  area o f  cr itica l im p o r ta n ce  is id e n ­
t if ic a t io n  o f  th e  h u m o ra l and  su p p ressor  e le ­
m e n t s  th a t  p o t e n t ia l l y  th w a r t  e n d o g e n o u s  
a n d  im m u n o t h e r a p e u t ic  l i m i t a t i o n  o f  t u ­
m o r a l g r o w t h .  E l im in a t io n  o f  th e s e  s u b ­
s ta n ces  is a g o a l for in v e s t ig a to r s . I f  m o le ­
cu les  p rod u ced  by th e  tu m o r have in h ib ito r y  
in flu en ces on  L A K  ce ll a c t iv ity , m o n o c lo n a l  
a n tib o d ie s  d e v e lo p e d  to  n e u tr a liz e  th is  s u p ­
p ress io n  m a y  p o te n t ia lly  be u sed  (T a b le  3 ).35
TABLE 2






Complement or Cell-Mediated 
Inhibition of Receptors for Growth Factors 




‘ Adapted from de Trlbolel el al.21
TABLE 3 
Current and Potential 
Immunotherapeutic Methods
Active Specific
e.g. autografts, “tumor vaccines"
Active Nonspecific
e.g. BCG inoculations 
Low-dose interferons
Adoptive
e.g. autologous lymphocyte infusions 
LAK cell implantations
Restorative





e.g. LAK with MAB
Lymphokine combinations 
(IL-2 and interferon)
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T h e  p r e se n c e  o f  th e  N K  c e l ls  in  g lio m a s ,  
w ith  th e ir  in h e r e n t  a n t itu m o r  ca p a c ity , and  
th e  a b ility  to  enh ance N K  c y to to x ic ity  w ith  
in terferons is  a p o te n t ia l fu ture experim enta l 
aven u e for im m u n o th e r a p y .9
T h e  u se  o f  n e w ly  iso la te d  ly m p h o k in e s ,  
a lo n e  or in  c o m b in a t io n  w i t h  e s ta b lis h e d  
ly m p h o k in e s ,  is  a p r o m is in g  area o f  fu tu re  
research. In te r le u k in -4  has th e  a b ility  to  g en ­
era te  L A K  c e l ls  and  is sy n e r g is t ic  w ith  IL -2  
in  th e  g e n e r a t io n  o f  L A K  c e l l s  in  m i c e . 50 
IL -4  a lso  a id s  in  T -c e l l  g r o w th  an d  d iffer ­
e n t ia t io n  e x c lu s iv e  o f  L A K  c e l l  g e n era tio n . 
O th er  c o m b in a tio n s  o f  ly m p h o k in es , such  as 
tu m o r  n e c r o s is  fa c to r  (T N F )  and  g a m m a -  
in t e r fe r o n , e x e r t  s y n e r g i s t i c  in  v iv o  a n t i ­
tu m o r  e f f e c t s  in  m i c e . 15 T o  d a te  n o n e  o f  
th ese c o m b in a tio n s  has been  a ttem p ted  in  the  
trea tm en t o f  h u m an  g lio m a ; con tro lled  trials 
have yet to  esta b lish  th e ir  efficacy  in v ivo .
Local im m u n o th era p y  via intraarterial in ­
fu s io n  m a y  p r e c lu d e  th e  n e c e s s i ty  o f  cra­
n i o t o m y  f o r  i n s t i l l a t i o n  o f  i m m u ­
n o th e r a p e u t ic  a g e n t s .  In te r fe r o n s  or T N F  
m ay be in jec ted  v ia  carotid  artery to  achieve  
h ig h  lo ca l co n c e n tr a t io n s  in  th e  tu m o r va s­
c u la tu r e , w h i le  m in im iz in g  s y s te m ic  to x ­
ic ity .
T h e  co m b in a tio n  o f  d ifferen t m od es o f  im ­
m u n o th era p y  h o ld s prom ise  for future trials; 
fo r  e x a m p le  t h e  u se  o f  a d o p t iv e  im m u ­
n o th era p y  su ch  as L A K  c e lls  w ith  c y to ly t ic  
m o n o c lo n a l a n t ib o d ie s  m ay b e  a fu tu re  c o n ­
s id e r a t io n .  I t  is  c o n c e iv a b le  th a t w it h  th e  
ad d ed  fa c to r  o f  A D C C  a m o re  favorab le re­
sponse in  tu m o r  red u ction  m ay  be ach ieved . 
L A K  ce lls  co u ld  be gen erated  and in fused  in -  
tr a t u m o r a lly  in  c o m b in a t io n  w ith  m o n o ­
clonal a n tib o d ie s  and cy to k in es  such as T N F  
or interferon-"y, w h ich  syn ergize w ith  in ter­
le u k in -2 in  m a in ta in in g  th e  c e ll-m e d ia te d  
c y t o t o x ic i t y  a n d  A D C C  a c t iv i t y  o f  th e  i n ­
fused  c e l l s . 1,2
“ B i o l o g i c a l  r e s p o n s e  m o d i f i c a t i o n ” or  
" B io m o d u la tio n ” is th e  central th em e to  the  
app roach  to  im m u n o th e r a p y . I t  d e fin e s  th e  
d ir e c t io n  t o  b e  fo l lo w e d  in  fu tu r e  im m u ­
n o th erap eu tic  practice .
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